9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation




Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies

You are here:
Estimated reading time: < 1 min


Advanced Cancers

Estimated Enrollment: 142

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 2014-0640|NCI-2015-00693

Study First Received: April 14, 2015

Last Updated: March 10, 2017

Estimated Primary Completion Date: June 2019

Primary Outcome Measures:

Maximum Tolerated Dose (MTD)|Disease Control

Sponsors and Collaborators:

M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02419495

Was this article helpful?
Views: 6